Enzyme News and Research

RSS

Defective chemical bond in biological tissue may be the reason for diseases, say researchers

Researchers at Vanderbilt University Medical Center led by Billy Hudson, Ph.D., have discovered a new chemical bond in biological tissue, a fundamental discovery that helps explain evolutionary adaptation in the animal kingdom and may shed light on human disease.

4 Sep 2009

94-year-old crusader seeks ban on trans fats in the American diet

Fred Kummerow, a 94-year-old University of Illinois veterinary biosciences professor emeritus who still conducts research on the health effects of trans fats in the diet, filed the petition with the FDA last month. The petition is now posted on the FDA Web site, and public comments are invited. (See below for information on viewing the petition and making a comment.)

4 Sep 2009

StemCells’ novel neuroprotective approach for treating neurodegenerative diseases

StemCells, Inc. today announced the publication of preclinical data demonstrating for the first time that transplantation of its proprietary, purified human neural stem cells delays the loss of motor function in a mouse model of infantile neuronal ceroid lipofuscinosis (NCL).

4 Sep 2009

IND for Cytopia's CYT387 clears the FDA review

Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.

4 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

Atrium Innovations supports Wobenzym(R) brand development in Germany

Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany.

3 Sep 2009

THNN's Vice President to supervise the clinical research applications of SUPER MEAL RX

THNN Inc. (Transformation Health Nutrition Naturals Inc.) enthusiastically announces the appointment of Dr. Thoger Malmstrom to the position of Vice President for Nutritional Wellness Applications.

3 Sep 2009

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce a recent research publication by Harvard Medical School on their finding of DispersinB® enzyme specific substrate in Acinetobacter baumannii (A. baumannii).

3 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

Strelitz Diabetes Center awarded a two-year grant for 12-LO research

Scientists at Eastern Virginia Medical School's Strelitz Diabetes Center have been awarded a two-year grant totaling $472,683 by the Juvenile Diabetes Research Foundation (JDRF).

3 Sep 2009

Boron-based molecules can be used as new pharmacophores

Chemists and biologists have successfully demonstrated that specially synthesized boron compounds are readily accepted in biologically active enzymes, a move that, they say, is a proof of concept that could lead to new drug design strategies.

3 Sep 2009

New method for treating hand disorder discovered

Researchers in the Department of Orthopaedics at Stony Brook University Medical Center have developed an injectable form of the enzyme, collagenase, that significantly improves outcomes of Dupuytren's contracture (or disease), a debilitating disorder caused by progressive accumulation of collagen that deforms fingers and limits motion. Reported in September 3, 2009, issue of The New England Journal of Medicine, the study involved treatment of 308 patients with Duputren's disease in 16 sites nationwide. The results indicate that the injections are safe and effective.

3 Sep 2009

Scientists demonstrate the link between cancer and diesel fumes

Scientists here are the first to demonstrate that the link between diesel fume exposure and cancer lies in the ability of diesel exhaust to induce the growth of new blood vessels that serve as a food supply for solid tumors.

2 Sep 2009

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

2 Sep 2009

New study on behaviour of telomeres during cell division in cancerous human cells

A process that limits the number of times a cell divides works much differently than had been thought, opening the door to potential new anticancer therapies, researchers at UT Southwestern Medical Center report in the Aug. 7 issue of the journal Cell.

2 Sep 2009

LifeVantage granted third patent for Protandim

LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim’s® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.

2 Sep 2009

Intrexon purchases assets and operations of Avalon Pharmaceutical

Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the purchase of assets and operations of Avalon Pharmaceutical, Inc., a wholly-owned subsidiary of Clinical Data, Inc.

1 Sep 2009

Elsevier publishes second edition of Signal Transduction

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announces the publication of the new second edition of Signal Transduction edited by Bastien D. Gomperts, Ijsbrand M. Kramer and Peter E.R. Tatham.

1 Sep 2009

Natural food compounds may play a vital role in cancer treatment

Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy.

1 Sep 2009